Arcutis Biotherapeutics (ARQT) announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration to expand the indication of ZORYVE cream 0.3% for the treatment of plaque psoriasis in children down to the age of 2. If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor treatment indicated for plaque psoriasis in children down to age 2.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics’ Earnings Call: Growth Amid Challenges
- Arcutis Biotherapeutics price target raised to $25 from $20 at TD Cowen
- Arcutis Biotherapeutics: Promising Growth Driven by Zoryve’s Success and Strategic Initiatives
- Arcutis Biotherapeutics price target raised to $22 from $19 at H.C. Wainwright
- Arcutis Biotherapeutics Reports Strong Q2 2025 Growth